ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduce ...

财务状况 - 公司持续亏损,存在持续经营能力的重大不确定性[138,139,140] - 公司于2024年6月30日的现金及现金等价物仅为0.2百万美元,无法支持未来一年的计划运营[144] - 公司一直依靠公开和私募股权及债务融资来维持运营,此外还有来自合作伙伴的有限服务收入[177] - 公司在2024年6月30日和2023年12月31日分别拥有现金及现金等价物0.2百万美元和1.5百万美元[186] - 公司预计将继续产生亏损,并且预计亏损将随着产品候选药物的开发和监管审批的继续而增加[187] - 公司正在寻求通过公开或私募股权、债务融资或其他资本来源(如政府资助、合作、战略联盟、非核心资产剥离或与第三方的许可安排)来为其运营提供资金[188,189] - 公司的经营活动在2024年上半年和2023年上半年分别使用了9.0百万美元和10.5百万美元现金[191,192,193] 临床试验进展 - 公司正处于临床试验阶段,尚未产生任何产品销售收入[136] - 公司在阿尔茨海默病临床试验中,治疗组患者大脑葡萄糖代谢活性较对照组显著提高,达到统计学显著性[148,150] - 公司认为,治疗效果最佳的是在轻度认知障碍(MCI)阶段的患者[151,152] - 公司之前在亨廷顿病临床试验中,治疗组在认知功能和心理指标方面也有改善[149] - 公司认为,阿尔茨海默病和亨廷顿病存在相似的病理特征和临床症状,治疗效果的相似性支持了药物在两种疾病中的潜在疗效[150] - 公司计划尽早识别MCI患者并给予治疗,以延缓疾病进展[151,152] - 公司正在进行阿尔茨海默病、头颈癌和胰腺癌等适应症的临床试验[163][164] - 公司之前暂停了亨廷顿病的研发,正在评估未来的发展策略[165] 研发费用 - 研发费用主要包括临床试验成本、员工薪酬福利、前期临床试验物料和设备折旧等[160][161] - 研发费用在2024年6月30日结束的三个月和六个月期间分别下降23%和18%,主要是由于SIGNAL-AD试验的减少、头颈癌试验暂停招募以及药品生产成本降低[171][175] 上市及股权融资 - 公司未能满足纳斯达克最低股东权益要求,面临被摘牌的风险[145,146] - 公司已获得延期至2024年9月30日前重新达到最低股东权益标准的机会[205] - 如果公司未能在期限内重新达标,其普通股可能会被纳斯达克摘牌,这将对股价和流动性产生负面影响[206,207] - 公司优先股在清算、解散和清盘时的分配权利优先于普通股[208,209] - 优先股转换为普通股将对现有普通股东产生摊薄[210,211] - 阿尔茨海默病药物发现基金可能会出售其持有的公司普通股,这可能会降低股价,不利于公司未来融资和并购[212,213] 收入来源 - 公司目前尚未产生任何产品销售收入,收入主要来自于与Surface Oncology的合作协议[157][158]

ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Our Company recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in early stages of Alzheimer’s disease (AD). The purpose of this report is to share additional data related to cognitive effects that may help clarify the goals of this study, how well it succeeded, an ...

Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington's disease based on similarities to neuroimmune pathology in Alzheimer's ROCHESTER, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer's disease (AD) with anti-Semaphorin 4D (SEMA4D) antibody, ...

Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical- stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that the last patient comple ...

Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that the last patient comple ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of (I.R.S. Em ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38624 Vaccinex, Inc. (Exact name of Registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of (I.R. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of (I.R.S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of (I.R.S. Emp ...